Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen is a company focused on developing novel gene and cell therapies that have the potential to improve the health and well-being of patients around the world, with a particular focus on retinal diseases. With their promising Modifier Gene Therapy Platform, the company is well-positioned to address unmet medical needs in various diseases such as Stargardt disease and AMD. Despite potential regulatory and clinical risks, the company's plan to initiate a Phase 3 study for their treatment in 3Q26 and strong potential for future revenues leads to a positive outlook for the stock.

Ocugen is a clinical-stage biopharmaceutical company with a negative outlook due to potential risks in achieving clinical endpoints demonstrating safety and efficacy for their modifier gene therapy platform and other therapeutic candidates. The company's financials and key data metrics, including potential M&A and collaborations, show potential upside if milestones are achieved, but the company faces stiff competition, potential IP infringement suits, and challenges in obtaining regulatory approval for its products. Its recent preclinical data and milestones for age-related macular degeneration and retinitis pigmentosa show promising results, but more data and regulatory approvals are needed to de-risk the stock.